Major R&D Pipeline
As of May 15, 2026
(Updated based on quarterly financial disclosure)
-
●：Development progress from January 2026 onwards
〇：Development progress from April 2025 onwards
Neurology
Dementia
*You can scroll to the left or right here
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 「Leqembi」(lecanemab/BAN2401) Treatment for Alzheimer’s disease (AD) / anti-Aβ protofibril antibody In-license (BioArctic) Injection (intravenous infusion, subcutaneous injection) Joint development with Biogen | ||||
| Early AD | 301 (Clarity AD) | European Union | ○ | Approval (April 2025) |
| Intravenous maintenance treatment for early AD (Additional Dosage and Administration) | 201/301 | China |
○ | Approval (September 2025) |
| UK | ○ | Approval (November 2025) |
||
| European Union | ● | Submission (accepted: January 2026) | ||
| South Korea | ○ | Submission (May 2025) | ||
| Maintenance treatment of subcutaneous injection formulation for early AD (360mg) | 301 | US | ○ | Approval (August 2025) |
| Initiation treatment of subcutaneous injection formulation for early AD (500mg) | 301 | Japan | ○ |
Submission (November 2025) |
| US | ● | Submission (accepted: January 2026) | ||
| China | ● | Submission (accepted: January 2026) | ||
| Preclinical AD (Additional Indication) | 303 (AHEAD 3-45) | JP/US/EU | PⅢ | |
| etalanetug/E2814 anti-MTBR tau antibody Collaboration (University College London) Injection | ||||
| Dominantly inherited AD (in combination with lecanemab) | Tau NexGen | JP/US/EU | PⅡ/Ⅲ | |
| Sporadic early AD (in combination with lecanemab) | 202 | JP/EU | PⅡ | |
| E2511 TrkA integrated synapse regenerant In-house Oral | ||||
| AD | - | US | PⅠ | |
| E2025 Anti-EphA4 antibody In-house Injection | ||||
| AD | - | US | PⅠ | |
Neurological diseases other than dementia
*You can scroll to the left or right here
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 「Dayvigo」(lemborexant/E2006) Insomnia treatment / Orexin receptor antagonist In-house Oral | ||||
| Insomnia disorder | 311 | China | ○ | Approval (May 2025) |
| evenamide/EA8001 Modulator of excessive glutamate release In-license (Newron) Oral | ||||
| Treatment-resistant schizophrenia with an inadequate response to at least two antipsychotics (Development conducted by EA Pharma) |
CT1 | Japan | ● | PⅢ |
| ledasorexton/E2086 Orexin receptor agonist In-house Oral | ||||
| Narcolepsy | 202 | JP/US/CH | ● | PⅡ |
Oncology
※左右にスクロールできます
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 「Lenvima/Kisplyx」(lenvatinib/E7080) Anticancer agent / kinase inhibitor In-house Oral | ||||
| In combination with anti-PD-1 therapy pembrolizumab, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication) | ||||
| Hepatocellular carcinoma (in combination with transcatheter arterial chemoembolization) | LEAP-012 | China | ○ | Approval (July 2025) |
| In combination with oral hypoxia-inducible factor-2 alpha inhibitor belzutifan, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication) | ||||
| Renal cell carcinoma | LITESPARK-011 | US | ● | Submission (accepted: January 2026) |
| Japan | ● | Submission (March 2026) | ||
| 「Halaven」(eribulin/E7389) Anticancer agent / microtubule dynamics inhibitor In-house Injection | ||||
| Monotherapy (Additional Formulation) | ||||
| Liposomal formulation | - | JP/EU | PⅠ | |
| In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation) | ||||
| Liposomal formulation | 120 | Japan | PⅠb/Ⅱ | |
| 「Tasfygo」(tasurgratinib/E7090) Anticancer agent / FGFR1, FGFR2, FGFR3 inhibitor In-house Oral | ||||
| Breast cancer | - | Japan | PⅠb | |
| taletrectinib/E7860 Anticancer agent / ROS1 inhibitor In-license (Nuvation Bio) Oral | ||||
| Non‑small cell lung cancer (ROS1‑positive) | TRUST- I/II | European Union | ● | Submission (accepted: March 2026) |
| farletuzumab ecteribulin (FZEC) /MORAb-202 Anticancer agent / Folate receptor α targeted antibody drug conjugate In-house Injection | ||||
| Ovarian cancer, peritoneal cancer, fallopian tube cancer (monotherapy or in combination with lenvatinib) | 201 | JP/US/EU | PⅠ/Ⅱ | |
| E7386 Anticancer agent / CBP/β-catenin interaction inhibitor Collaboration (PRISM BioLab) Oral | ||||
| Solid tumors (in combination with lenvatinib) | 102 | JP/US/EU/CH | PⅠb/Ⅱ | |
| Solid tumors | - | JP/US/EU | PⅠ | |
| H3B-6545 Anticancer agent / ERα inhibitor In-house Oral | ||||
| Breast cancer (in combination with CDK4/6 inhibitor palbociclib) | - | US/EU | PⅠb | |
| E7766 Anticancer agent In-house Injection | ||||
| Solid tumors | - | US/EU | PⅠb | |
Global Health
※左右にスクロールできます
| Disease | Sponsor of study | Region | Development Stage | |
|---|---|---|---|---|
| fosravuconazole/E1224 Antifungal agent / ergosterol synthesis inhibitor In-house Oral | ||||
| Eumycetoma *Supported by GHIT fund *Eisai is mainly responsible for non-clinical studies and the provision of the investigational drug. |
DNDi・Mycetoma Research Center of the University of Khartoum | Sudan | PⅡ | |
| SJ733 Antimalarial agent / ATP4 inhibitor Co-development (University of Kentucky) Oral | ||||
| Malaria *Supported by GHIT fund *Eisai is responsible for the provision of drug substance and formulation manufacturing |
University of Kentucky | Peru | PⅡ | |
| E1018 Antimalarial agent / protein synthesis inhibitor Co-development (Broad Institute) Oral | ||||
| Malaria *Supported by the U.S. Department of Defense *Discovered through collaboration with the Broad Institute |
Eisai | US | PⅠ | |
Gastrointestinal Disorders
※左右にスクロールできます
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 「MOVICOL」(AJG555) Chronic constipation treatment / polyethylene glycol preparation In-license (Norgine) Oral | ||||
| Chronic constipation in 1-year old pediatric patients (Additional Dosage and Administration) (Development conducted by EA Pharma) |
CT3 | Japan | ○ | Submission (October 2025) |
| AJM347 In-house Oral | ||||
| Inflammatory bowel disease (Joint development conducted by EA Pharma with Ensho Therapeutics, Inc.) | - | EU | PⅠ | |
| EA1080 In-house Oral | ||||
| Inflammatory bowel disease (Joint development conducted by EA Pharma with Ensho Therapeutics, Inc.) | - | EU | PⅠ | |
| EA3571 In-house Oral | ||||
| Metabolic dysfunction-associated steatohepatitis (Development conducted by EA Pharma) | - | Japan | PⅠ | |
Other
※左右にスクロールできます
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| E6742 Treatment for Systemic lupus erythematosus / TLR 7/8 inhibitor In-house Oral | ||||
| Systemic lupus erythematosus | 201 | Japan | ● | PⅡ |